INTRA-CELLULAR THERAPIES, INC. for INTRA-CELLULAR THERAPIES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception; Part D6 protected classes resolution.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW SPERLING | — |
Health Issues HCR
HR 2630/S. 652: Safe Step Act - provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - provisions regarding regulation of pharmacy benefit managers.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW SPERLING | — |
Taxation/Internal Revenue Code TAX
HR 3938/S. 866: American Innovation and Jobs Act - provisions regarding research and development tax credit amortization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW SPERLING | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.